CSIMarket
 


Achilles Therapeutics Plc  (ACHL)
Other Ticker:  
 

Achilles Therapeutics Plc's Leverage Ratio

ACHL's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of 0% Achilles Therapeutics Plc improved Leverage Ratio in forth quarter 2022 to 0.07, a new company high.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2022, 12 other companies have achieved lower Leverage Ratio than Achilles Therapeutics Plc in the IV Quarter 2022. While total ranking remained the same in the forth quarter 2022 compared to the previous quarter at no. 163 .

Explain Leverage Ratio?
Who are ACHL Customers?
What are ACHL´s Total Liabilities?


ACHL Leverage Ratio (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Equity Change -31.94 % -31.94 % -31.94 % -31.94 % -
Y / Y Total Liabilities Change -3.79 % -3.79 % -3.79 % -3.79 % -
Leverage Ratio MRQ 0.07 0.07 0.07 0.07 0.05
ACHL's Total Ranking # 163 # 163 # 142 # 174 # 189
Seq. Equity Change 0 % 0 % 0 % -31.94 % 0 %
Seq. Total Liabilities Change 0 % 0 % 0 % -3.79 % 0 %



Leverage Ratio forth quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 74
Overall Market # 163


Leverage Ratio Statistics
High Average Low
0.07 0.06 0.05
(Dec 31 2022)   (Dec 31 2021)




Financial Statements
Achilles Therapeutics Plc's Equity $ 197 Millions Visit ACHL's Balance sheet
Achilles Therapeutics Plc's Total Liabilities $ 15 Millions Visit ACHL's Balance sheet
Source of ACHL's Sales Visit ACHL's Sales by Geography


Cumulative Achilles Therapeutics Plc's Leverage Ratio

ACHL's Leverage Ratio for the trailling 12 Months

ACHL Leverage Ratio

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Equity TTM Growth -31.94 % -31.94 % -31.94 % -31.94 % -
Y / Y Total Liabilities TTM Growth -3.79 % -3.79 % -3.79 % -3.79 % -
Leverage Ratio TTM 0.07 0.07 0.06 0.06 0.05
Total Ranking TTM # 138 # 3 # 4 # 0 # 274
Seq. Equity TTM Growth 0 % 0 % 0 % -31.94 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 0 % -3.79 % 0 %


On the trailing twelve months basis Due to repayements of liabilities of 0% Achilles Therapeutics Plc has not changed Leverage Ratio in the 12 months ending in IV Quarter 2022 to 0.07, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 11, during the past 12 months, other companies have achieved lower Leverage Ratio than Achilles Therapeutics Plc. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2022, compared to the prior period, from 3 to 138.

Explain Leverage Ratio?
Who are ACHL Customers?
What are ACHL´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 12
Healthcare Sector # 75
Within the Market # 138


trailing twelve months Leverage Ratio Statistics
High Average Low
0.12 0.11 0.1
(Dec 31 2022)   (Dec 31 2021)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2022, within Biotechnology & Pharmaceuticals Industry Leverage RatioDec 31 2022 MRQ Total LiabilitiesDec 31 2022 MRQ Equity
Crispr Therapeutics Ag  0.20 $ 367.578  Millions$ 1,875.479  Millions
Compugen Ltd  0.20 $ 15.184  Millions$ 77.680  Millions
In8bio Inc   0.20 $ 4.433  Millions$ 22.732  Millions
Atyr Pharma Inc   0.19 $ 13.682  Millions$ 71.284  Millions
Anavex Life Sciences Corp   0.19 $ 25.579  Millions$ 135.124  Millions
Cardiol Therapeutics inc   0.19 $ 7.527  Millions$ 39.986  Millions
Hillevax Inc   0.19 $ 49.982  Millions$ 267.229  Millions
Inhibikase Therapeutics Inc   0.19 $ 3.901  Millions$ 21.035  Millions
Vectivbio Holding Ag  0.18 $ 39.231  Millions$ 213.368  Millions
Adverum Biotechnologies Inc   0.18 $ 33.293  Millions$ 181.518  Millions
Vor Biopharma Inc   0.18 $ 45.487  Millions$ 250.607  Millions
Tarsus Pharmaceuticals Inc   0.18 $ 34.963  Millions$ 192.900  Millions
Bio techne Corp  0.18 $ 328.395  Millions$ 1,827.106  Millions
Surrozen Inc   0.18 $ 13.434  Millions$ 76.001  Millions
Jounce Therapeutics inc   0.16 $ 29.438  Millions$ 183.112  Millions
Biontech Se  0.16 $ 3,610.320  Millions$ 22,462.272  Millions
Iovance Biotherapeutics Inc   0.16 $ 79.898  Millions$ 499.638  Millions
Relay Therapeutics Inc   0.16 $ 149.553  Millions$ 950.218  Millions
Tenaya Therapeutics Inc   0.15 $ 35.569  Millions$ 243.376  Millions
Aura Biosciences Inc   0.14 $ 28.352  Millions$ 195.583  Millions
Replimune Group Inc   0.14 $ 83.205  Millions$ 595.345  Millions
Iteos Therapeutics Inc   0.14 $ 91.659  Millions$ 663.332  Millions
4d Molecular Therapeutics Inc   0.13 $ 30.509  Millions$ 231.337  Millions
Springworks Therapeutics Inc   0.13 $ 72.050  Millions$ 558.192  Millions
Organovo Holdings Inc   0.13 $ 2.790  Millions$ 22.289  Millions
Bioatla Inc   0.12 $ 21.610  Millions$ 180.339  Millions
Cabaletta Bio Inc   0.12 $ 12.448  Millions$ 104.520  Millions
Molecular Partners Ag  0.12 $ 27.092  Millions$ 235.166  Millions
Argenx se  0.11 $ 320.562  Millions$ 2,813.699  Millions
Protara Therapeutics Inc   0.11 $ 11.207  Millions$ 102.083  Millions

Date modified: 2023-03-23T07:01:17+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com